Thermo Fisher Scientific Inc.
TMOHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeThermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. At a $183.03B market cap, Thermo Fisher Scientific Inc. ranks as a large-cap company within healthcare. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Market Cap
$183.03B
Beta
0.88
P/E (TTM)
27.11
P/E (Fwd)
18.04
EPS (TTM)
$18.17
EPS (Fwd)
$27.30
ROE
13.5%
ROA
5.0%
Cash
$3.26B
Total Debt
$43.16B
Free CF
$5.52B
52W Change
24.2%
Annual Financials
Cash vs Debt
Thermo Fisher Scientific Inc. carries $43.16B in total debt against $3.26B in cash reserves — debt is roughly 13.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $5.52B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 13.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 5.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $39.21B to $44.56B.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TMO.